Uji klinis PPOK di Colorado
15 studi untuk PPOK mencari peserta di lokasi di Colorado.
Kota di Colorado
Teks studi resmi (Bahasa Inggris)
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
- Alpine Clinical Research Center - Boulder - 47th Street- Site Number : 8400005, Boulder
- Critical Care Pulmonary & Sleep Associates- Site Number : 8400081, Lakewood
Menerima pesertaFase 3
Usia 40 hingga 80 · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT07190222To Evaluate the Effect of EXPD-101/FXS7553 Compared With Placebo in Patients With COPD Over 52 Weeks of Treatment
- Lynn Institute of Denver, Aurora
Menerima pesertaFase 2
Usia 40 hingga 85 · Semua jenis kelamin · Diperbarui 30 Sep 2026 · NCT07684820A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
- National Jewish Health Medical Center, Denver
Menerima pesertaFase 2
Usia 40 hingga 75 · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT07759245An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients With Severe Emphysema
- UCHealth - Medical Center of the Rockies, Loveland
Menerima peserta
Usia 40 hingga 80 · Semua jenis kelamin · Diperbarui 17 Sep 2026 · NCT06035120Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD
- National Jewish Health, Denver
Menerima pesertaFase 2
Usia 40 ke atas · Semua jenis kelamin · Diperbarui 4 Sep 2026 · NCT07059091A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
- Research Site, Aurora
- Research Site, Denver
Menerima pesertaFase 3
Usia 40 hingga 80 · Semua jenis kelamin · Diperbarui 26 Agu 2026 · NCT06283966eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
- GSK Investigational Site, Lakewood
Menerima pesertaFase 3
Usia 40 hingga 75 · Semua jenis kelamin · Diperbarui 28 Jul 2026 · NCT07177339MoblO2 to Maintain Oxygenation
- National Jewish Health, Denver
Menerima peserta
Usia 25 hingga 95 · Semua jenis kelamin · Diperbarui 22 Jul 2026 · NCT07704567SPIROMICS Study of Early COPD Progression (SOURCE)
- National Jewish Health, Denver
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 30 hingga 55 · Semua jenis kelamin · Diperbarui 3 Jun 2026 · NCT05033990Breathe Easier With Tadalafil Therapy for Dyspnea in COPD-PH
- Rocky Mountain Regional VA Medical Center, Aurora, CO, Aurora
Menerima pesertaFase 2
Usia 35 hingga 89 · Semua jenis kelamin · Diperbarui 15 Mei 2026 · NCT05937854Right Ventricular Response to Exercise Among Patients With Chronic Obstructive Pulmonary Disease
- University of Colorado Anschutz Medical Campus, Aurora
Menerima peserta
Usia 40 ke atas · Semua jenis kelamin · Diperbarui 8 Mei 2026 · NCT07576894Phenotyping Resting and Exertional Right Ventricular Dysfunction Among Patients With Chronic Obstructive Pulmonary Disease
- University of Colorado Anschutz Medical Campus, Aurora
Menerima peserta
Usia 40 ke atas · Semua jenis kelamin · Diperbarui 8 Mei 2026 · NCT05896579Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
- GSK Investigational Site, Aurora
Menerima pesertaFase 3
Usia 40 hingga 80 · Semua jenis kelamin · Diperbarui 9 Apr 2026 · NCT06961214PiMZ Longitudinal Cohort (PiMZ Logic)
- National Jewish Health, Denver
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 16 Jan 2026 · NCT06505603PRagmatic EVAluation of a Quality Improvement Program for People Living With Modifiable High-risk COPD.
- University of Colorado, Denver
Menerima peserta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 12 Okt 2023 · NCT05306743Dari ClinicalTrials.gov, data diambil 2 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.